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Second cancers after breast cancer treatment
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Objective. Breast irradiation, adjuvant chemotherapy, and tamoxifen are associated with an increased risk of second cancers
that may manifest decades after treatment. The objective of our study was to analyze the second cancers after breast cancer
treatment in our centre.
Materials and methods. Retrospective analysis of 46/1046 patients with breast cancer stages I and II, treated with conservative
surgery plus radiation therapy from January 1993 to December 2009 who developed second cancers after the treatment. Median
age: 60 years (37–79). 70% of the patients (pts) were stage I and 30% stage II. 25 (54%) of the pts received adjuvant chemotherapy,
medium cycle 6 (0–12), with anthracyclines (30%) and anthracycline–taxanes (13%). 89% received hormone therapy. All patients
were treated with 50Gy radiation therapy to the whole breast in 25 fractions± regional nodes with or without a boost to the
primary tumor bed of 16–20Gy in fractions 8–10. Kaplan–Meier curves have been used for the statistical analysis of survival.
Results. With a median follow-up of 135 months (39–199 months) 5% of the patients developed second cancers. The median time
until second cancer appearance was 81 months. 15 pts (33%) developed second breast cancer with a median time of 67 months
and age of 50 years and 31 pts (67%) other cancers with a median time of 83 months and age of 63 years. Endometrial cancer
was the second most frequent localization in 5 pts (11%), all of them had received adjuvant tamoxifen. Only 2 pts presented lung
cancer. The overall survival at 15 years was 69% and without signiﬁcant difference between breast and no breast second cancers
(p=0.43).
Conclusions. According to our results breast cancer was the most frequent second cancer in patients after breast cancer treatment,
followed by endometrial cancer in patients that received tamoxifen. Lung cancer was infrequent.
http://dx.doi.org/10.1016/j.rpor.2013.03.112
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Purpose. To evaluate the outcome in patients (pts) diagnosed with ductal carcinoma in situ (DCIS) of the breast treated with
conservative surgery and postoperative radiotherapy.
Materials and methods. We analyze 84 pts treated with conservative surgery and whole breast postoperative radiotherapy, 50Gy,
2Gy/fx plus electron beam boost in 21 (25%). Age, mean: 53.12 (31–72) years. Tumor size, mean: 0.7 cm (8.5–0.2 cm). Tumor margin:
clear > 5mm: 54pts (64.3%); Clear 1 – ≤5mm: 18 pts (21.4%); Involved: 6pts (7.1%); unknown: 6 (7.1%). Tumor grade I: 24 (28.6%);
grade II: 11 (13.1%); grade III 18 (21.4%); unknown: 31 (36.9%). Hormonal receptor status: Positive: 51 (60.7%); Negative 5 (6%);
Unknown 28 (33.3%). Pts were analysed in follow-up for overall survival (OS) disease-free survival (DFS), local and contralateral
breast recurrence and distant metastases.
Results. Mean follow-up: 9.96 years. Overall survival (OS): mean 17.11 years (IC95% 15.88–18.34) actuarial at 5 and 10 years: 97
and 91%, respectively. OS cancer-speciﬁc: mean 18.48 years (IC 95% 17.93–19.02) OS actuarial cancer-speciﬁc at 5 and 10 years:
98%. DFS global: mean 17.74 years (IC 95%: 16.85–18.62) actuarial at 5 and 10 years: 96% and 91%, respectively. DFS (breast): mean
18.12 years. DFS (breast) at 5 and 10 years: 94%. Two pts former diagnosed of DCIS G-III, developed visceral metastases due to
inﬁltrating ductal carcinoma of breast (IDC) and died. There were 4 breast recurrences: 1 pt suffered from ipsilateral (IDC) not in
the same quadrant. 1 pt suffered from contralateral (DCIS) 2 pts developed ipsilateral DCIS recurrence. Mean time to recurrence:
7.3 years. All ipsilateral breast recurrences were salvaged with mastectomy. All women with breast recurrence are free of disease.
Conclusion. Although prognosis of DCIS of breast is excellent and its mortality is virtually zero some high grade DCIS could be
misdiagnosed, IDC should be ruled out carefully.
http://dx.doi.org/10.1016/j.rpor.2013.03.113
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Introduction. Breast cancer is the most frequent in women. Rates of survival and local control in early stages of breast cancer are
excellent thanks to combination therapies.
Objective. To analyse retrospectively the survival and local control of diagnosed breast carcinoma patients treated with conser-
vative surgery and adjuvant radiotherapy.
Methods. From January 1997 to December 2000, 292 women with stages 0–III breast cancer were treated with conservative
surgery±adjuvant chemotherapy± radiotherapy±adjuvant hormonal therapy in HUA-Txagorritxu. 75 of them were excluded
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for presenting bilateral breast carcinomas (7), second tumors (19), loss of tracking or overprinting boost in another center (49).
22.11% were stage 0, 12.01% stage I, 22.58% stage II and 1.38% stage III. All women received 2D-radiotherapy to additional doses
of 45–50.4Gy and 10–14Gy as an additional boost on a surgical bed to standard fractionation. In the case of patients with more
than three positive axillary nodes they also received 45–50.4Gy on supraclavicular fossa.
Results. The median follow-up was 12.9 years (95% CI: 2.1–13.8 years). 10-Year local control and overall survival was 98.2% and
96.8%, respectively. By stages 10-year survival rates were 100% in stage 0, 99.1% in stage I and 87.5% in stage II. Stage III was not
assessable by the low sample size. Regarding local control rates at 10 years in stages 0, I and II, were about 100%, 97.5% and 97.9%,
respectively. The majority of the systemic recurrences were at bone level.
Conclusions. The data obtained in our hospital conﬁrm the excellent results of the combined treatments in the early stages of
breast cancer being comparable to those published in literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.114
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Introduction. The S-BBC is a very rare disease, accounting for only 1–3% of all breast cancers. We have received in our center seven
cases of S-BBC. The treatment relies on surgery, chemotherapy and radiation therapy. No standard treatment guidelines exist
for the management of S-BBC. Current evidence indicates similar survival rates compared to early-staged breast cancer. The
difﬁculty in treatment planning varies greatly case by case therefore is a great challenge for radiotherapy planning.
Materials and methods. We report a review of one case. A 46 years old woman presented S-BBC in 2003. The patient presented
nodules in both breasts. The mammography revealed bilateral suspicious lumps and no suspicious lymph nodes. The extension
study showed no distant metastasis. The patient was scheduled for bilateral tumorectomy and axillary lymphadenectomy. The
histological diagnose was right breast invasive ductal carcinoma, pT1cpN1aM0, high grade and positive hormonal receptors, and
left breast colloid carcinoma, pT1cpN0M0, positive hormonal receptors. The patient received adjuvant chemo and radiotherapy.
The volume of treatment was delivered to the whole breast followed by a boost dose to the tumor bed, bilaterally. The supra-
clavicular and axillary lymph nodes of right breast were also treated. The energy used was 6MV on LINAC. The dose was 45Gy
(1.8Gy per fraction). The tumor bed received an additional dose of 10Gy with 10MeV electrons. Early side effects were bilateral
G1 epitelitis. In the follow-up the patient showed no local relapses or distant metastasis.
Conclusion. The challenges of the treatmenthavebeen raised concerninghow to reducedoseof radiation tonormal tissues, prevent
overdose due to overlap in midline tangential ﬁelds, while maintaining tumour control and minimizing secondary effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.115
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Introduction. Traditionally, the administration of the boost in the conservative treatment of breast cancer has been performed
sequentially. The 3DRT-SIB technique (three-dimensional conformal simultaneously integrated boost) allows to reduce the total
time of treatment.
Purpose. Assessment of the acute toxicity in patients treated with 3DRT-SIB.
Methods and materials. Between May 2010 and May 2012, 150 women were treated in our Unit after being operated on for breast
carcinoma with conservative surgery. 33 patients received neoadjuvant chemotherapy (22%), 61 patients received adjuvant
chemotherapy (41%) prior to radiotherapy. Their ages were comprised between 28 and 84 years old (average 57 years old). Post-
surgical stage: pT0 (post-QT) 8%, pT1 66%, pT2 23%, pT3 2% and pT4 1%; pN0 69%, pN1 28%, pN2 2% and pN3 1%. None of them
showed distant metastases. The total dose administered to the mammary gland was 42.4Gy or 50Gy, delivering a simultaneous
boost with photon in the lumpectomy area. 0.4Gy per fraction in 82% and 0.6Gy per fraction in 18% were administered, reaching a
total dose ranged from 52.4 to 66Gy. Among the total of women, 24 of them (over 65 years old) were treated with hypofractionated
treatment, administering 2.65Gy daily with concomitant boost of 0.6Gy per fraction, reaching a dose of 54.4Gy in 16 fractions.
Results. We valued the dermal acute toxicity according to Common Terminology Criteria for Adverse Events (CTC v3.0), observing
radiodermatitis G0 9%, G1 55%, G2 31% and G3 4%. No acute toxicity was observed in G4. In patients with hypofractionated
treatment, toxicity was G0 8%, G1 74% and G2 21%, detecting no acute effect equal to or greater than G3.
Conclusions. The treatment with 3DRT-SIB is safe, presenting a similar toxicity to sequential boost with electrons, and allowing a
reduction of the total time of radiotherapy of 1–2 weeks.
http://dx.doi.org/10.1016/j.rpor.2013.03.116
